A 2026 Parkinson’s disease mouse study reported that benzhexol hydrochloride induced a measurable hallucination-like behavior state in 6-OHDA parkinsonian mice, and an integrated behavior classifier separated that state from non-PDVH mice with AUC = 0.96 and Youden index = 0.875.1 The careful interpretation is behavioral modeling, not proof that mice had human visual hallucinations. Research …
A 2026 Glia analysis found a shared microglial transcriptional program across 5 neurodegenerative contexts: ALS, frontotemporal dementia, Alzheimer’s disease, aging, and Parkinson’s disease.1 The standout marker was SPP1, a gene encoding osteopontin, but the finding is a cellular-state signal rather than a ready diagnostic test. Research Highlights Cross-disease microglia converged: the integrated dataset covered ALS, …
A 2026 mouse study found that long-term CoQ10 exposure reduced working-memory errors in Purkinje-cell-specific Drp1-deficient mice, tying the behavioral rescue to Coa6 binding and support for mitochondrial respiratory-chain function.1 The result supports a narrow mechanistic CoQ10-Coa6 pathway under neuronal mitochondrial dysfunction while leaving human memory-supplement claims untested. Research Highlights Working memory improved in a mouse …
A 2025 Nature Communications study found that Alzheimer’s-like mice lost locus coeruleus noradrenergic axons in the olfactory bulb early: 14% loss by 2 months, 27% by 3 months, and 33% by 6 months, before broader forebrain axon degeneration appeared.1 Early smell loss may reflect a specific brainstem-to-olfactory circuit injury, while smell testing still needs biomarker …
A 2026 meta-analysis of 54 human studies found that 8-hydroxy-2′-deoxyguanosine rose in Parkinson’s disease, while F2-isoprostanes did not show a statistically confirmed Parkinson’s signal; type 2 diabetes showed much larger peripheral oxidative-stress elevations than Parkinson’s disease for both biomarkers. Research Highlights Parkinson’s DNA-oxidation signal was moderate: Msigwa et al. pooled 5 Parkinson’s disease studies with …
A 2026 humanized P301S tauopathy mouse study found that syntaxin-6 knockout partly rescued early motor impairment from months 1 to 4, protected gait at 5.5 months, reduced frailty (p = 0.0052), and reduced superficial-cortex neurodegeneration at 3 months (p = 0.0055).1 The finding strengthens syntaxin-6 as a tauopathy modifier, but it is still mouse genetics, …
A 2026 PNAS study found that TMEM175 behaves as a pH-sensitive lysosomal channel relevant to Parkinson’s risk biology.1 Acidifying the luminal side from pH 7.4 to 4.7 activated proton conductance, shifted reversal potential, and tied H57 to H+ and K+ flux. Research Highlights Acidification activated TMEM175: lowering luminal-side pH from 7.4 to 4.7 increased inward …